ST Elevation Myocardial InfarctionFRAME-AMI3NCT06227754
OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
A study testing Angiography-guided PCI group and Optical coherence tomography-guided PCI group in people with ST Elevation Myocardial Infarction and Myocardial Infarction, run by Chonnam National University Hospital at 18 sites in South Korea.
Trial summary
The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- ST Elevation Myocardial Infarction, Myocardial Infarction
- What is being tested?
- Angiography-guided PCI group and Optical coherence tomography-guided PCI group
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,500 participants
- Where
- 18 sitesSouth Korea
- Study dates
- 25 Mar 2024to 31 Dec 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject must be at least 19 years of age
- Acute ST-segment elevation myocardial infarction (STEMI)
- STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1
- Primary percutaneous coronary intervention (PCI) in < 12 h after the onset of symptoms for STEMI patients
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
Who cannot join
- Target lesions not amenable for PCI by operators' decision
- Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)
- Creatinine clearance ≤30 ml/min/1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)
- Cardiogenic shock (Killip class IV) at presentation
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
- Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
Show all 9Show fewer
- Pregnancy or breast feeding
- Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
- Unwillingness or inability to comply with the procedures described in this protocol
Trial locations and contacts
18 sites in 1 country. Contact the study team or a site near you to ask about taking part.
18 sites in 1 country
South Korea18 sites, 18 recruiting
- Recruiting
Kyungpook National University Hospital
Daegu, Daegu, 41944
Nam Kyun Kim, MD, PhD, namkyun.kim@knu.ac.kr
Nam Kyun Kim, MD, PhD
- Recruiting
Yeungnam University Medical Center
Daegu, Daegu, 42415
Ung Kim, MD, PhD, woongwa@gmail.com
Ung Kim, MD, PhD
- Recruiting
Daegu Catholic University Medical Center
Daegu, Daegu, 42472
Jin Bae Lee, MD, PhD, noblewise1@gmail.com
Jin Bae Lee, MD, PhD
- Recruiting
Chonnam National University
Gwangju, Gwangju, 61469
Young Joon Hong, MD, PhD, hyj200@hanmail.net
Seung Hun Lee, MD, PhD, lsh8602@naver.com
- Recruiting
Wonkwang University Hospital
Iksan, Iksan, 54538
Donghyeon Joo, MD, dhjoozz@naver.com
Kyeong Ho Yun, MD, PhD
- Recruiting
International St. Mary's Hospital
Incheon, Incheon, 22711
Hyung-Bok Park, MD, PhD, hyungbok7@gmail.com
Hyung-Bok Park, MD, PhD
- Recruiting
Jeju National University Hospital
Jeju City, Jeju-do, 63241
Song-Yi Kim, MD, PhD, ttoromom@jejunu.ac.kr
Song-Yi Kim, MD, PhD
- Recruiting
Jeonbuk National University Hospital
Jeonju, Jeonju, 54907
Yi Sik Kim, MD, PhD, dr.kimesik@gmail.com
Sang-Rok Lee, MD, PhD
- Recruiting
Gyeongsang National University Hospital
Jinju, Jinju, 52727
Jin-Sin Koh, MD, PhD, kjs0175@gmail.com
Jin-Sin Koh, MD, PhD
- Recruiting
Kyung Hee University Hospital
Seoul, Seoul, 02447
Weon Kim, MD, PhD, mylovekw@hanmail.net
Weon Kim, MD, PhD
- Recruiting
Samsung Medical Center
Seoul, Seoul, 06351
Joo-Yong Hahn, MD, PhD, jooyong.hahn@gmail.com
Joo Myung Lee, MD, MPH, PhD, drone80@hanmal.net
- Recruiting
Chung-Ang University Hospital
Seoul, Seoul, 06973
Wang Soo Lee, MD, PhD, wslee1227@cau.ac.kr
Wang Soo Lee, MD, PhD
- Recruiting
Ewha Womans University Seoul Hospital
Seoul, Seoul, 07804
Sanghoon Shin, MD, PhD, nephilla99@gmail.com
Sanghoon Shin, MD, PhD
- Recruiting
Ewha Womans University Mokdong Hospital
Seoul, Seoul, 07985
Sodam Jung, MD, PhD, cvdosam@gmail.com
Sodam Jung, MD, PhD
- Recruiting
Korea University Guro Hospital
Seoul, Seoul, 08308
Dong Oh Kang, MD, PhD, gelly9@naver.com
Dong Oh Kang, MD, PhD
- Recruiting
St. Carollo Hospital
Suncheon, Suncheon, 57931
Jang Hyun Cho, MD, PhD, goodnew8@naver.com
Jang Hyun Cho, MD, PhD
- Recruiting
Uijeongbu St Mary's Hospital
Uijeongbu-si, Uijeongbu, 11765
Chan Joon Kim, MD, PhD, godandsci@naver.com
Chan Joon Kim, MD, PhD
- Recruiting
Ulsan University Hospital
Ulsan, Ulsan, 44033
Eun Seok Shin, MD, PhD, sesim1989@gmail.com
Eun Seok Shin, MD, PhD
About this study
Official title: Randomized Controlled Trial of Optical Coherence Tomography Versus Angiography for Culprit Lesion Revascularization in Patients With Acute Myocardial Infarction
The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).
Read the detailed description
Percutaneous coronary intervention (PCI) is a standard treatment for significantly stenotic lesion of coronary arteries, especially in the setting of acute myocardial infarction (AMI) where timely reperfusion is important. Traditionally, visual assessment by coronary angiography has been the main tool to identify coronary artery disease and guide revascularization. However, it is known that angiography alone is unable to adequately evaluate significance of stenotic lesion or optimization status of the stent, and that angiography suffers from high intra- and interobserver variability. Thus, methods for intracoronary imaging and/or physiology have been developed to aid these limitations.
During the PCI procedure, intravascular imaging devices such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on lesion characteristics and optimal stent implantation with regard to appropriate reference segment, stent expansion, stent apposition, and possible acute complications. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the randomized controlled trials were limited with small sample size and dealt with very selected lesion subsets such as chronic total occlusion (CTO) or long lesions. Moreover, although some studies observed similar clinical outcomes between IVUS-guided PCI and OCT-guided PCI, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI.
Currently, randomized controlled trial to support beneficial impact of OCT-guided PCI, especially in patients with acute myocardial infarction (AMI) is lacking. One randomized clinical trial in 2016 with 240 non-ST-elevation myocardial infarction patients have reported higher postprocedural fractional flow reserve and similar incidence of major adverse cardiac events with the use of OCT compared to angiography alone, but this study mostly focused on immediate physiologic findings of OCT-guided PCI and only demonstrated clinical outcomes on short-term follow-up. Although the ILUMIEN IV trial evaluated efficacy of OCT-guided PCI among high risk patients including lesions were considered to be responsible for a recent myocardial infarction, there was no apparent difference in the target-vessel failure at 2 years. There is no randomized controlled trial that can provide information on its long-term clinical impact, and current clinical guidelines puts OCT on Class 2a recommendation as an alternative for IVUS, with the exception of ostial left main disease.
In this regard, randomized controlled trial comparing clinical outcome following PCI in patients with AMI where procedural optimization is performed under OCT-guidance or angiography alone would provide valuable evidence to enhance prognosis after treatment of AMI. Therefore, FRAME-AMI 3 trial has been designed to compare clinical outcomes after PCI for infarct-related artery using either OCT-guided or angiography-guided strategy.
- Being tested
- Angiography-guided PCI group, Optical coherence tomography-guided PCI group
- Keywords
- ST-segment elevation MI, Optical coherence tomography, Intravascular imaging, Primary PCI
- Medical subject headings
- ST Elevation Myocardial Infarction, Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Angiography-guided PCI groupProcedure or surgery
The PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended.
Optical coherence tomography-guided PCI groupProcedure or surgery
[Stent Optimization]
- Stent Expansion: Visually assess residual angiographic diameter stenosis <10% "AND" ① In non-LM lesions: In-stent minimal lumen area (MSA) >80% of the average reference lumen area "OR" >4.5 mm2 ② In LM lesion: MSA>7 mm2 for distal LM and >8 mm2 for proximal LM
- Stent Apposition: No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and < 1mm length) of the stent over its entire length against the vessel wall
- Edge Dissection:
No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as >60° of the circumference of the vessel at site of dissection and/or >2 mm in length of dissection flap)
| Study group | Role | What they receive |
|---|---|---|
| Angiography-guided PCI | Active comparator | The PCI procedure in this group will be performed as standard procedure. Receives: Procedure: Angiography-guided PCI group |
| Optical coherence tomography-guided PCI | Experimental | Use of OCT will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT after stent implantation will be mandatory. In this group, the recommendations for selecting reference segment, selecting appropriate size of stent, and stent optimization are as follows. OPTIS imaging catheter (Abbott Vascular) will be used for the imaging arm according to MLD MAX algorithm. Receives: Procedure: Optical coherence tomography-guided PCI group |
What is being measured
The primary outcome is the main question the study is designed to answer.
Target vessel failure
a composite of cardiac death, target-vessel myocardial infarction, clinically-driven target-vessel repeat revascularization, definite or probable stent thrombosis
Measured: 2 years after last patient enrollment
Secondary outcomes (12)
All-cause death
All-cause death
Measured: 2 years after last patient enrollment
Cardiac death
Cardiac death
Measured: 2 years after last patient enrollment
Rate of any myocardial infarction
Any myocardial infarction, defined by Forth Universal definition of myocardial infarction
Measured: 2 years after last patient enrollment
Rate of spontaneous myocardial infarction
Spontaneous myocardial infarction, defined by Forth Universal definition of myocardial infarction
Measured: 2 years after last patient enrollment
Rate of procedure-related myocardial infarction
Procedure-related myocardial infarction, defined by ARC II definition
Measured: 2 years after last patient enrollment
Rate of any revascularization
Any revascularization (clinically-driven or ischemia-driven)
Measured: 2 years after last patient enrollment
Rate of target vessel revascularization
Target vessel revascularization
Measured: 2 years after last patient enrollment
Rate of stent thrombosis
Definite or probable stent thrombosis, defined by ARC II definition
Measured: 2 years after last patient enrollment
Total procedural time
Total procedural time (primary PCI to end of the procedure including amount of staged procedure)
Measured: at least 1 week after index procedure
Total fluoroscopy time
Total fluoroscopy time (primary PCI to end of the procedure including amount of staged procedure)
Measured: at least 1 week after index procedure
Total amount of contrast use
Total amount of contrast use (primary PCI to end of the procedure including amount of staged procedure)
Measured: at least 1 week after index procedure
Incidence of contrast-induced nephropathy
Incidence of contrast-induced nephropathy, defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure.
Measured: at least 1 week after index procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2024
- Study start25 Mar 2024
- Primary completion31 Mar 2031 (estimated)
- Study completion31 Dec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ST Elevation Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective, multicenter, open-label, randomized controlled trial to compare clinical outcomes between optical coherence tomography (OCT)-guided versus angiography-guided PCI in AMI patients undergoing PCI.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chonnam National University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Samsung Medical Center
- Responsible party
- Principal investigator, Young Joon Hong, Chonnam National University Hospital
- Investigators
- Young Joon Hong, MD, PhD, Principal investigator, Chonnam National UniversityJoo-Yong Hahn, MD, PhD, Principal investigator, Samsung Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06227754
- Sponsor's protocol ID
- FRAMEAMI220716
- Acronym
- FRAME-AMI3
- Status last verified
- May 2026
- First submitted
- 31 Dec 2023
- Last updated
- 8 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Controlled Trial of Optical Coherence Tomography Versus Angiography for Culprit Lesion Revascularization in Patients With Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT06227754
- Acronym / sponsor ID
- FRAME-AMI3 / FRAMEAMI220716
- Keywords
- ST-segment elevation MI, Optical coherence tomography, Intravascular imaging, Primary PCI
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,500 participants (estimated)
- Lead sponsor
- Chonnam National University HospitalUniversity, hospital or other
- Collaborators
- Samsung Medical Center
- Study start
- 25 Mar 2024 (actual)
- Primary completion
- 31 Mar 2031 (estimated)
- Study completion
- 31 Dec 2031 (estimated)
- First posted
- 29 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to compare clinical outcomes between optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI).
Detailed description
Percutaneous coronary intervention (PCI) is a standard treatment for significantly stenotic lesion of coronary arteries, especially in the setting of acute myocardial infarction (AMI) where timely reperfusion is important. Traditionally, visual assessment by coronary angiography has been the main tool to identify coronary artery disease and guide revascularization. However, it is known that angiography alone is unable to adequately evaluate significance of stenotic lesion or optimization status of the stent, and that angiography suffers from high intra- and interobserver variability. Thus, methods for intracoronary imaging and/or physiology have been developed to aid these limitations.
During the PCI procedure, intravascular imaging devices such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on lesion characteristics and optimal stent implantation with regard to appropriate reference segment, stent expansion, stent apposition, and possible acute complications. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the randomized controlled trials were limited with small sample size and dealt with very selected lesion subsets such as chronic total occlusion (CTO) or long lesions. Moreover, although some studies observed similar clinical outcomes between IVUS-guided PCI and OCT-guided PCI, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI.
Currently, randomized controlled trial to support beneficial impact of OCT-guided PCI, especially in patients with acute myocardial infarction (AMI) is lacking. One randomized clinical trial in 2016 with 240 non-ST-elevation myocardial infarction patients have reported higher postprocedural fractional flow reserve and similar incidence of major adverse cardiac events with the use of OCT compared to angiography alone, but this study mostly focused on immediate physiologic findings of OCT-guided PCI and only demonstrated clinical outcomes on short-term follow-up. Although the ILUMIEN IV trial evaluated efficacy of OCT-guided PCI among high risk patients including lesions were considered to be responsible for a recent myocardial infarction, there was no apparent difference in the target-vessel failure at 2 years. There is no randomized controlled trial that can provide information on its long-term clinical impact, and current clinical guidelines puts OCT on Class 2a recommendation as an alternative for IVUS, with the exception of ostial left main disease.
In this regard, randomized controlled trial comparing clinical outcome following PCI in patients with AMI where procedural optimization is performed under OCT-guidance or angiography alone would provide valuable evidence to enhance prognosis after treatment of AMI. Therefore, FRAME-AMI 3 trial has been designed to compare clinical outcomes after PCI for infarct-related artery using either OCT-guided or angiography-guided strategy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Prospective, multicenter, open-label, randomized controlled trial to compare clinical outcomes between optical coherence tomography (OCT)-guided versus angiography-guided PCI in AMI patients undergoing PCI.
| Arm | Type | Receives |
|---|---|---|
| Angiography-guided PCI | Active comparator | Procedure: Angiography-guided PCI groupThe PCI procedure in this group will be performed as standard procedure. |
| Optical coherence tomography-guided PCI | Experimental | Procedure: Optical coherence tomography-guided PCI groupUse of OCT will be allowed at any step of PCI (pre-PCI, during PCI and post-PCI), but OCT after stent implantation will be mandatory. In this group, the recommendations for selecting reference segment, selecting appropriate size of stent, and stent optimization are as follows. OPTIS imaging catheter (Abbott Vascular) will be used for the imaging arm according to MLD MAX algorithm. |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Subject must be at least 19 years of age
- Acute ST-segment elevation myocardial infarction (STEMI)
- STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block1
- Primary percutaneous coronary intervention (PCI) in < 12 h after the onset of symptoms for STEMI patients
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
Key exclusion criteria (9 listed)
- Target lesions not amenable for PCI by operators' decision
- Ostial lesions located in left main vessel or right coronary artery (left main body or distal bifurcation lesions can be enrolled by operator's discretion)
- Creatinine clearance ≤30 ml/min/1.73 m2 and not on dialysis (chronic dialysis dependent patients are eligible for enrolment regardless of creatinine clearance)
- Cardiogenic shock (Killip class IV) at presentation
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Angiography-guided PCI groupThe PCI procedure in this group will be performed as standard procedure. After deployment of stent, stent optimization will be done based on angiographic findings. The optimization guided by angiography should meet the criteria of angiographic residual diameter stenosis less than 10% by visual estimation and the absence of flow limiting dissection (≥Type C dissection). When angiographic under-expansion of the stent is suspected, adjunctive balloon dilatation will be strongly recommended. | Procedure or surgery | Angiography-guided PCI |
| Optical coherence tomography-guided PCI group[Stent Optimization] 1. Stent Expansion: Visually assess residual angiographic diameter stenosis <10% "AND" ① In non-LM lesions: In-stent minimal lumen area (MSA) >80% of the average reference lumen area "OR" >4.5 mm2 ② In LM lesion: MSA>7 mm2 for distal LM and >8 mm2 for proximal LM 2. Stent Apposition: No major malapposition (defined as a distance from stent strut to adjacent intima ≥400 um and < 1mm length) of the stent over its entire length against the vessel wall 3. Edge Dissection: No major edge dissection in the proximal or distal reference segments, defined as 5 mm from the edge of the stent, extended to media layer with potential to provoke flow disturbances (defined as >60° of the circumference of the vessel at site of dissection and/or >2 mm in length of dissection flap) | Procedure or surgery | Optical coherence tomography-guided PCI |
Primary outcome
Target vessel failure
Time frame: 2 years after last patient enrollment
a composite of cardiac death, target-vessel myocardial infarction, clinically-driven target-vessel repeat revascularization, definite or probable stent thrombosis
12 secondary outcomes
All-cause death
Time frame: 2 years after last patient enrollment
Cardiac death
Time frame: 2 years after last patient enrollment
Rate of any myocardial infarction
Time frame: 2 years after last patient enrollment
Rate of spontaneous myocardial infarction
Time frame: 2 years after last patient enrollment
Rate of procedure-related myocardial infarction
Time frame: 2 years after last patient enrollment
Rate of any revascularization
Time frame: 2 years after last patient enrollment
Rate of target vessel revascularization
Time frame: 2 years after last patient enrollment
Rate of stent thrombosis
Time frame: 2 years after last patient enrollment
Total procedural time
Time frame: at least 1 week after index procedure
Total fluoroscopy time
Time frame: at least 1 week after index procedure
Total amount of contrast use
Time frame: at least 1 week after index procedure
Incidence of contrast-induced nephropathy
Time frame: at least 1 week after index procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Individual participant dataSharing planned: Yes. After publication of main paper, de-identified data will be shared upon reasonable requests after discussion by Executive Committee.
Related trials for ST Elevation Myocardial Infarction
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
Incremental Prognostic Utility of CBC-derived Inflammatory Indices After Incomplete Coronary Revascularization: Association With 12-months Cardiovascular Outcomes
STEMI, High Risk NSTEMI
RecruitingObservational study
SuperSaturated Oxygen Comprehensive Observational Registry
STEMI - ST Elevation Myocardial Infarction, AMI
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Young Joon Hong, MD, PhD principal investigator
Chonnam National University
Joo-Yong Hahn, MD, PhD principal investigator
Samsung Medical Center
18 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Angiography-guided PCI group and Optical coherence tomography-guided PCI group in people with ST Elevation Myocardial Infarction and Myocardial Infarction, run by Chonnam National University Hospital at 18 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 18 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Seung Hun Lee, MD, PhD (82-2-220-6246, lsh8602@naver.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Target vessel failure (time frame: 2 years after last patient enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026; AzTrials last refreshed its copy on 7 Nov 2026.